IL-5 Antibody (YA4710)
(Synonyms: IL5; Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL-5 nanobody; )IL-5 Antibody (YA4710) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to IL-5.
-
Host:
Mouse
-
Application:
ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in Phosphate-buffered solution.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|
| Dilution Ratio | 1:5000-100000 |
Product Details
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in Phosphate-buffered solution.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
IL-5 is a central cytokine regulating eosinophil differentiation, survival, and activation. Its receptor-specific signaling underlies both disease pathogenesis and therapeutic interventions, including monoclonal antibodies and receptor agonists for experimental models.
-
Subcellular Localization
Secreted
-
Expression
Tissue_specificity:Present in peripheral blood mononuclear cells -
Isoforms & Post-Translational Modification
P05113 has 2 isomers: P05113-1: 15238 Da (predicted); P05113-2: 13982 Da (predicted).
-
Subunit
Homodimer; disulfide-linked (PubMed:22528658, PubMed:8483502). Interacts with IL5RA (PubMed:1495999, PubMed:22153509). Interacts with CSF2RB (PubMed:1495999)
-
SwissProt ID
-
Synonyms
IL5; Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL-5 nanobody;
Documentation
[1]. Philbin VJ, et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol. 2012 Jul;130(1):195-204.e9. [Content Brief]
[2]. Elias M, et al. IL-36 in chronic inflammation and fibrosis - bridging the gap? J Clin Invest. 2021 Jan 19;131(2):e144336. [Content Brief]
[3]. Queen D, et al. Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development. Front Cell Dev Biol. 2019 Dec 4;7:317. [Content Brief]
[4]. Wagener BM, et al. Synergistic Inhibition of β2-adrenergic Receptor-mediated Alveolar Epithelial Fluid Transport by Interleukin-8 and Transforming Growth Factor-β. Anesthesiology. 2015 May;122(5):1084-92. [Content Brief]
[5]. Boutet MA, et al. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential. Int J Mol Sci. 2019 Mar 13;20(6):1257. [Content Brief]
[6]. Penna G, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009 Apr 1;69(5):480-93. [Content Brief]
[7]. Foreback JL, et al. Blood mononuclear cell production of TNF-alpha and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway. J Leukoc Biol. 1998 Jul;64(1):124-33. [Content Brief]
[8]. Speer EM, et al. Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro. PLoS One. 2018 May 1;13(5):e0196352. [Content Brief]
Powered by Bioz
